Antisense Therapeutics (ASX:ANP) has commenced dosing in a muscular dystrophy mouse model of Duchenne muscular dystrophy to assess the potential clinical utility of ATL1102 in combination with dystrophin restoration drugs. …
Antisense Therapeutics says dosing has commenced in combination study
September 12, 2022 Australian Biotech
Latest Video
New Stories
-
Merck joins with Omico to improve access to cancer trials in Australia
May 22, 2025 - - Latest News -
New Zealand announces 12-month prescriptions in 2025 Budget
May 22, 2025 - - Latest News -
'I think we have to step up and help him to understand that he's got to deliver on it'
May 22, 2025 - - Latest News -
TGA approves first-of-a-kind medicine for early symptomatic Alzheimer’s disease
May 21, 2025 - - Latest News -
Examples are important as evidence of the problem, but be prepared to defend them
May 21, 2025 - - Latest News -
Trump administration invites companies to 'align' US pricing under MFN plan
May 21, 2025 - - Latest News -
NDIS minister restates the importance of 'nothing about us, without us!'
May 20, 2025 - - Latest News